"Most things that are new, with the exception of healthcare and biotech, start as technology and then move over into their proper classification," said Moberg. "We believe that we run a very diversified portfolio, but don't believe yet that the index providers have fully caught up to how…
News
- Meet the wildly successful portfolio manager whose history degree is his secret weapon for ...
- A startup that wants to better understand the relationship our gut has to our brain just raised $66 ...
Kallyope, a biotech startup working to map out the gut-brain axis, has raised $66 million. The series B round will help the company get some of its programs nearer to human clinical trials and continue research on the relationship between the gut and its microbes and the brain. The hope is that…
- Mission Pharmacal enters into agreement with MainPointe Pharmaceuticals to purchase and ...
Mission Pharmacal Company is a privately held pharmaceutical company based in San Antonio, Texas. ... functions independently while their product and service offerings can be linked together to offer customizable solutions to a wide array of forward-thinking pharmaceutical and biotech companies…
- Ultragenyx reports 4Q loss
Losses, adjusted for pretax gains, came to $2.27 per share. The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $2 per share. The biotechnology company posted revenue of $2.4 million in the period.
- Bobby Alford, Baylor College of Medicine fixture, dies at 87
Dr. Bobby Alford, a Baylor College of Medicine fixture for more than half a century, died Tuesday. He was 87. Alford served in a number of leadership roles at Baylor, including dean of medicine and chairman of the department of otolaryngology. He grew the National Space Biomedical Research…